Characteristics | Patients included (n=66) |
Age (years), median (range) | 57.0 (20.0–75.0) |
Body mass index (kg/m2), n (%) | |
<18 | 2 (3.0) |
18–25 | 43 (65.2) |
25–30 | 14 (21.2) |
≥30 | 7 (10.6) |
ASA score, n (%) | |
1 | 23 (35.4) |
2 | 39 (60.0) |
3 | 2 (3.1) |
4 | 1 (1.5) |
Missing | 1 (–) |
Type of treatment, n (%) | |
First-line | 29 (43.9) |
Recurrence | 37 (56.1) |
Previous treatment, n (%) | |
Chemotherapy | 20 (30.8) |
Chemotherapy + surgery | 45 (69.2) |
Missing | 1 (–) |
Co-morbidities and treatment | |
Diabetes, n (%) | 3 (4.5) |
High blood pressure, n (%) | 11 (16.7) |
ACEIs/ARBs, n (%) | 4 (6.1) |
I ntra-operative parameters | |
Peritoneal Carcinomatosis Index, median (range) | 8 (0.0–33.0) |
Missing | 5 (–) |
Visceral resections, n (%) | |
0 | 26 (39.4) |
1–2 | 32 (48.5) |
>3 | 8 (12.1) |
Peritonectomy procedures, n (%) | |
0 | 8 (12.1) |
Level I | 22 (33.3) |
Level II | 25 (37.9) |
Level III | 11 (16.7) |
CC-score, n (%) | |
CC-0 | 63 (95.5) |
CC-1 | 3 (4.5) |
Operative time (min), median (range) | 320 (147.0–720.0) |
Missing | 1 (–) |
Cisplatin (mg/m2), median (range) | 75 (34.0–100.0) |
Missing | 1 (–) |
Epidural analgesia, n (%) | 29 (45.3) |
Missing | 2 (–) |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, American Society of Anesthesiologists; CC-score, Completeness Cytoreduction score.